Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $750,000.00 in Stock

Key Points

• Alphatec Holdings EVP Craig E. Hunsaker sold 50,000 shares of company stock for a total of $750,000.00, resulting in a 3.45% reduction in his ownership.
• The company's stock recently traded down 2.0% to $14.90, with a 12-month trading range between $4.88 and $15.46.
• Alphatec reported a quarterly earnings per share of $0.02, beating analyst expectations and showing a 27.5% year-over-year revenue increase.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig E. Hunsaker sold 50,000 shares of the company's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the transaction, the executive vice president owned 1,400,018 shares of the company's stock, valued at $21,000,270. This trade represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alphatec Stock Down 2.0%

ATEC stock traded down $0.30 during midday trading on Thursday, hitting $14.90. The company's stock had a trading volume of 4,026,670 shares, compared to its average volume of 2,697,044. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $15.46. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The firm's 50-day moving average is $11.58 and its 200-day moving average is $11.26. The company has a market cap of $2.20 billion, a PE ratio of -13.19 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The business's quarterly revenue was up 27.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.29) EPS. On average, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Several institutional investors have recently added to or reduced their stakes in ATEC. Comerica Bank grew its stake in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after buying an additional 1,248 shares in the last quarter. Quarry LP raised its position in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares during the period. Larson Financial Group LLC purchased a new position in shares of Alphatec in the 1st quarter worth approximately $54,000. Nisa Investment Advisors LLC increased its position in shares of Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Alphatec during the 4th quarter valued at approximately $76,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 1st. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Barclays reiterated an "overweight" rating and issued a $22.00 price target (up from $21.00) on shares of Alphatec in a research note on Monday. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Finally, Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 target price for the company in a report on Monday, June 16th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and a consensus target price of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.